A-485 has been used as a p300 regulated RelA acetylation inhibitor to study the effect of fatty acid oxidation (FAO) derived cytoplasmic acetyl-CoA on CD47 transcription and protein stability via citrate/acetyl-CoA mediated RelA acetylation in glioblastoma.
[1]